Doug Hirsch: Hey there! This is Doug. Thank you for the question. First of all, we’re very excited about this partnership of course. We’ve invested a tremendous amount of time and effort to be the preferred technology partner across the healthcare ecosystem. We think that our multi PBM marketplace, plus our brand, plus great pricing really makes us the player of choice for a program such as this. Obviously Express is one of the largest PBMs and they chose us to be their exclusive partner for this program, which is called Price Assure powered by GoodRx. So we launched the pilot in Q4, and it uses the technology for RxNXT that we acquired back in 2022, and it’s really beautiful and how simply it works. Basically, an Express Scripts member is eligible, just present their existing Express Script card at the pharmacy and they get the better price of their commercial price and/or the discount price provided by GoodRx. This enables out of pocket claims to count towards the members’ deductible and also gives full visibility of the claims to the payer.
So we launched it in Q4. Again, it’s gone really well. This is early, I want to be clear. But we are really, really excited with the momentum. We’re extremely pleased with the progress, and it’s performing better than we anticipated. Now, as we’re talking today, even Express Scripts’ is educating and rolling planned sponsors to try €“ you know to bring more people onto the program and again, we’re just really, really pleased with it. We think that it’s going to expand market opportunity, expand our reach and address the market.
Operator: Thank you. One moment for our next question. And that will come from the line of Charles Rhyee with Cowen. Your line is open.
Lucas Romanski: Hi! This is Lucas on for Charles. When I look at your guidance, it seems to imply that we’re going to see sequential revenue growth throughout the year. Can you walk us through what is contributing to that sequential ramp? What revenue streams you’re expecting to drive that? And then how should we think about the cadence of revenue throughout the year?
Karsten Voermann: Sure. Thanks for the question Lucas. This is Karsten speaking again. A couple of things. I think first of all, as we’ve talked about it historically, we see our highest growth business being our pharma manufacturer solutions business. That business grew approximately 36% Y-o-Y for the full year last year, and we expect it to continue to be delivering significant growth results at a faster rate than other lines of business. That said, it also referenced as contributors to our overall growth rate. The fact that we’ve seen the growth of our non-grocery retailers’ increase from the third quarter to the fourth quarter. You might recollect that we talked about on the third quarter earnings call non-grocery retailers seeing about 8% y-o-y growth relative to the about 12.5%, 13% rounded growth in the fourth quarter of non-grocery retailers, so that business as well as performing at.
Finally, it seems like Doug addressed on the prior question associated with the ESI Cigna initiative are also contributors to growth as well. So I think those are in priority the ordering of where I think you’d see the growth coming from, again the largest nominal amount of dollar growth coming from our pharma manufacturers solutions business.
Operator: Thank you. One moment for our next question. And that will come from the line of Michael Cherny with Bank of America. Your line is open.
